Xintela develops treatment for aggressive breast cancer

Xintela has decided that the company's next focus in it’s  oncology programme will be triple-negative breast cancer, which is an aggressive form of breast cancer that often metastasizes and has a poor prognosis. This decision was made based on the accumulated positive preclinical results using proprietary function blocking antibodies in cell experiments and in a validated tumor model.

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that accounts for 10-15% of all breast cancer diagnoses. It is far more aggressive than other breast cancer types due to a higher degree of metastases and a tendency to relapse following treatment. Aggressive cancers such as TNBC are a challenge for healthcare systems and there is an urgent need to find new, better targeted treatment strategies that will improve survival and the quality of life for these patients.

Xintela has previously announced positive preclinical results in glioblastoma, an aggressive brain tumor and that the company is evaluating other aggressive cancer types. Based on accumulated preclinical data showing that the company's integrin α10 antibodies inhibit TNBC cell function and reduce the growth of TNBC in a tumor model, Xintela has now decided to develop targeted treatment for TNBC. Xintela has previously filed a patent application covering the use of integrin α10 antibodies for the treatment of aggressive cancers including TNBC.

“The positive results further validate our patent-protected target molecule integrin α10β1 for the treatment of aggressive cancers and is another important milestone for the oncology programme and our subsidiary Targinta AB. In addition, we have identified an antibody that has the potential to become a successful product for the treatment of triple-negative breast cancer and other aggressive cancer types”, says Xintela's CEO Evy Lundgren-Åkerlund.

Xintela AB